Fredun Pharmaceuticals Reports 90% Jump in Q2 Net Profit to ₹19 Crore on Strong Demand

MUMBAI — Formulation manufacturer Fredun Pharmaceuticals has announced its financial results for the quarter ending September, registering a 90 per cent jump in net profit to ₹19 crore, compared to ₹10 crore during the corresponding period last year. The growth was attributed to better demand across its product lines.

The company's revenue for the quarter rose by 85 per cent to ₹266 crore, up from ₹144 crore in the previous year. Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) saw a 91 per cent increase, reaching ₹43 crore compared to ₹22 crore a year ago.

Fredun Medhora, Managing Director of Fredun Pharmaceuticals, stated that the core formulations business is improving in efficiency and adding higher-margin products, while newer segments like pet care, mobility, nutrition, and dermaceuticals have entered a high-growth phase.

“These businesses carry better margins, so as they grow, they are steadily raising the quality of earnings. Fredun GX is now present in 19 states and pharmacies with distributors giving strong acceptance and repeat orders,” Medhora said.

In recent strategic moves, Fredun acquired a 26 per cent stake in Goodman Vetcare in September at a valuation of ₹300 crore. Goodman has planned over eight new stores and targets a revenue of ₹100 crore by FY31. Additionally, the company acquired Furlicks from USV and its subsidiary Wellbeing Nutrition in September 2026, marking its entry into the pet wellness market.

Furlicks produces oral strips covering skin and coat, gut health, joint care, calming, oral care, and multivitamins. Fredun plans to launch 16 new products over the next six to nine months, expanding its portfolio from 6 to 22 Stock Keeping Units (SKUs). These launches will introduce new formats such as cold-extruded, air-dried, and freeze-dried products, alongside functional biscuits. The company has also launched a pet healthcare knowledge platform named PAWTALKS on YouTube and Instagram.

“Pet care is one of the fastest-changing categories, as more pet parents treat their pets as family. The acquisition of stake in Goodman Vetcare and launch of PAWTALKS brings the company closer to a complete pet-wellness,” Medhora added. He also noted that the company is expanding capacity to build a large single-location manufacturing unit in the country while widening its product basket and strengthening its balance sheet.

"Fredun Pharmaceuticals' latest financial performance highlights how strong demand in core formulations combined with strategic diversification can drive substantial top-line and bottom-line growth. By entering high-margin adjacent sectors like pet wellness through targeted acquisitions and product line expansions, the company is effectively building a resilient business model. Managing manufacturing capacity alongside portfolio diversification will be key to sustaining this growth momentum." — Dr. Shishir Gupta, Founder & CEO, StartupLanes